Bottle Label 5 mg (71610 0603 08)
Not available.*
Tadalafil Tablet, Film Coated
Product Images NDC 71610-603
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-603). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena Pharma Solutions (TN)
10 (Tadalafil Tablets Usp 1)
10 (Tadalafil Tablets Usp 2)
This appears to be a table showing the difference in blood pressure measurements (Systolic BP and Diastolic BP) between taking Tadalafil and placebo, measured in mmHg, while standing and lying down and at various times (in hours) after taking the medication. The table includes some incomprehensible characters, which may be a result of errors in .*
10 (Tadalafil Tablets Usp 3)
This appears to be a table showing blood pressure (systolic) readings in standing and supine positions, along with some unidentified data represented by the text "aohowo" and "Aohowd". It also appears to be comparing the effects of a combination of Tadalafil 20mg and doxazosin 8mg with a placebo and doxazosin 8mg. The data is represented over a time period of 0-24 hours post-dose.*
10 (Tadalafil Tablets Usp 4)
This is a record of different doses of tadalafil and doxazosin administered at 8:00 am, along with placebos. The effects on systolic BP (blood pressure) are also recorded over time. No additional information is available.*
10 (Tadalafil Tablets Usp 5)
This document shows the concentration of plasma tadalafil in mcg/L over time after administering different doses of tadalafil. The graph displays the concentration levels for a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. The time scale ranges from 0 to 120 hours.*
10 (Tadalafil Tablets Usp 6)
This text provides information regarding the change from the baseline in IPSS total score for Tadalafil 5mg and placebo treatments. The treatment duration in weeks is also mentioned. The asterisk symbol is used to indicate a statistically significant difference in IPSS total score between the two treatments with a p-value of less than 0.01.*
10 (Tadalafil Tablets Usp 7)
The text describes a study that evaluates the effectiveness of Tadalafil 5 mg versus a placebo on the change from baseline in IPSS total score (a measure of urinary symptoms in men with prostate enlargement) over a certain duration of treatment in weeks. The asterisk next to the "p<0.01" indicates that the treatment with Tadalafil showed a statistically significant improvement compared to placebo.*
10 (Tadalafil Tablets Usp 8)
10 (Tadalafil Tablets Usp 9)
This text appears to be a table showing the results of a study comparing Tadalafil 5mg to a placebo. The table shows a significant difference between the two treatments with a p-value of <0.01. The data is related to the change from the baseline in the IPSS total score. However, without additional context or an explanation of what the IPSS total score represents, it is difficult to draw further conclusions.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
